Literature DB >> 2231595

Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses.

H Yang1, J Henkin, K H Kim, J Greer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2231595     DOI： 10.1021/jm00173a008

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  5 in total

1.  (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.

Authors:  S Sperl; U Jacob; N Arroyo de Prada; J Stürzebecher; O G Wilhelm; W Bode; V Magdolen; R Huber; L Moroder
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct.

Authors:  S Muto; M Imai; Y Asano
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

3.  Development of a Mammalian suspension culture for expression of active recombinant human urokinase-type plasminogen activator.

Authors:  Erica Atkins; Stephanie Zamora; Britny J Candia; Amy Baca; Robert A Orlando
Journal:  Cytotechnology       Date:  2005-09       Impact factor: 2.058

4.  Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19.

Authors:  Yong-Soon Cho; Jae-Gook Shin
Journal:  Transl Clin Pharmacol       Date:  2022-03-09

5.  Application of molecular modeling to urokinase inhibitors development.

Authors:  V B Sulimov; E V Katkova; I V Oferkin; A V Sulimov; A N Romanov; A I Roschin; I B Beloglazova; O S Plekhanova; V A Tkachuk; V A Sadovnichiy
Journal:  Biomed Res Int       Date:  2014-05-20       Impact factor: 3.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.